MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
745.77
-0.84
-0.11%
After Hours: 741.00 -4.77 -0.64% 19:31 03/13 EDT
OPEN
754.55
PREV CLOSE
746.61
HIGH
758.98
LOW
741.90
VOLUME
438.30K
TURNOVER
--
52 WEEK HIGH
820.12
52 WEEK LOW
474.60
MARKET CAP
78.84B
P/E (TTM)
17.98
1D
5D
1M
3M
1Y
5Y
1D
Regeneron Pharmaceuticals (REGN) Valuation Check After Recent Share Price Cooling
Simply Wall St · 23h ago
Is Eli Lilly's Weight Loss Empire in Trouble?
The Motley Fool · 1d ago
Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries
TipRanks · 2d ago
FDA APPROVES EYLEA HD FOR RARE PEDIATRIC DISEASE, REDEEMING PRIORITY REVIEW VOUCHER - FEDERAL REGISTER WEBSITE
Reuters · 2d ago
FDA: DETERMINED SUPPLEMENTAL APPLICATION FOR EYLEA HD, APPROVED NOV 19, 2025, MEETS CRITERIA FOR REDEEMING PRIORITY REVIEW VOUCHER
Reuters · 2d ago
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
The Motley Fool · 3d ago
Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs
Reuters · 3d ago
Regeneron: Fairly Valued Now After A Stellar Upswing
Seeking Alpha · 3d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.